Korro Bio, Inc. (KRRO) Stock

Korro Bio, Inc. (KRRO) is a Healthcare stock trading at $13.14 (as of 2026-08-21), with a market capitalization of $193.49M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Korro Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing genetic medicines that use RNA editing. It works on treatments for rare and highly prevalent diseases.

Understand Korro Bio, Inc.: how it makes money

Korro Bio develops and commercializes genetic medicines that use RNA editing to treat rare and highly prevalent diseases, including alpha-1 antitrypsin deficiency, and makes money through the commercialization of those therapies.

Profit depends on successfully turning RNA-editing medicine development into approved, commercially available genetic medicines, with clinical evidence like sustained editing and target protein presence in the body serving as key proof points.

Business quality (Weak): Clinical execution is tracked through RNA-editing effectiveness and dosing progress, but the latest reported operating margin is deeply negative and revenue is shown as 0.0B.

Bull case

  • Sustained target editing signal: Sustained Editing Efficiency is reported at 60.0 percent.
  • Early clinical dosing progress: Phase 1/2a REWRITE Healthy Volunteer Dosing Completion Percentage is reported at 80.0 percent, with 24 healthy volunteers dosed across the tested program.

Bear case

  • No reported revenue in the latest quarter: Revenue is shown as 0.0B for the period ending 2025-09-30, so commercialization cash flow is not evident from this snapshot.
  • Material profitability pressure: Operating margin is reported at -1764.9, indicating significant losses relative to revenue in the latest period.
  • Durability and concentration targets must keep holding up: Target protein concentration is reported as 35.0 one week after initial dose and 45.0 at week 13, meaning durability and consistency of the biological outcome remain critical.
Valuation — source: SEC EDGAR (first-party)
Price$13.14
Market Cap$193.49M
Price / Book1.87
Price / Sales177.52
FCF Yield-65.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$6.39M
Net Margin-1834.5%
Revenue Growth (YoY)181.5%
EPS Growth (YoY)33.2%
FCF Growth (YoY)1.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-5.64 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderPoint72 Asset Management, L.P. ($25.48M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORam Aiyar
Employees112
CountryUS
IPO Date2019-10-03

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • PepGen Inc. (PEPG)
  • Journey Medical Corporation (DERM)
  • Corbus Pharmaceuticals Holdings, Inc. (CRBP)
  • Tonix Pharmaceuticals Holding Corp. (TNXP)
  • Oramed Pharmaceuticals Inc. (ORMP)
  • Nkarta, Inc. (NKTX)
  • Tharimmune, Inc. (CNTN)
  • Cue Biopharma, Inc. (CUE)
KRRO earnings history · KRRO institutional & insider holders · KRRO KPIs & operating metrics · KRRO financials · KRRO investor presentations & press releases · KRRO SEC filings · KRRO peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.